FDA
-
-
-
-
-
-
-
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Solid Biosciences (SLDB) Reiterated at Market Outperform by Citizens After FDA Alignment
-
-
-
-
-
-
-
Solid Biosciences doses first patient in gene therapy trial for rare disease
-
-
-
-
-
-
-
Solid Biosciences gets FDA rare pediatric disease status for SGT-212
-
-
-
-
-
-
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
-
-
-
-
-
-
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Solid Biosciences (SLDB)
-
323,566 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

